Harvard
Jensen, ME, Galli, A
, Thomsen, M, Jensen, KL
, Thomsen, GK, Klausen, MK
, Vilsbøll, T, Christensen, MB, Holst, JJ, Owens, A, Robertson, S, Daws, L, Zanella, D, Gether, U
, Knudsen, GM & Fink-Jensen, A 2020, '
Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent',
Neurochemistry International, bind 138, 104772, s. 104772.
https://doi.org/10.1016/j.neuint.2020.104772
APA
Jensen, M. E., Galli, A.
, Thomsen, M., Jensen, K. L.
, Thomsen, G. K., Klausen, M. K.
, Vilsbøll, T., Christensen, M. B., Holst, J. J., Owens, A., Robertson, S., Daws, L., Zanella, D., Gether, U.
, Knudsen, G. M., & Fink-Jensen, A. (2020).
Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.
Neurochemistry International,
138, 104772. [104772].
https://doi.org/10.1016/j.neuint.2020.104772
CBE
Jensen ME, Galli A
, Thomsen M, Jensen KL
, Thomsen GK, Klausen MK
, Vilsbøll T, Christensen MB, Holst JJ, Owens A, Robertson S, Daws L, Zanella D, Gether U
, Knudsen GM, Fink-Jensen A. 2020.
Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.
Neurochemistry International. 138:104772.
https://doi.org/10.1016/j.neuint.2020.104772
MLA
Vancouver
Author
Jensen, Mathias E ; Galli, Aurelio
; Thomsen, Morgane ; Jensen, Kathrine L
; Thomsen, Gerda K ; Klausen, Mette K
; Vilsbøll, Tina ; Christensen, Mikkel B ; Holst, Jens J ; Owens, Anthony ; Robertson, Sabrina ; Daws, Lynette ; Zanella, Daniele ; Gether, Ulrik
; Knudsen, Gitte M ; Fink-Jensen, Anders. /
Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. I:
Neurochemistry International. 2020 ; Bind 138. s. 104772.
Bibtex
@article{4caea4637d124c1f8da62e95c63facbc,
title = "Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent",
abstract = "INTRODUCTION: A solid body of preclinical evidence shows that glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the effects of substance use disorder related behaviors. The mechanisms underlying these effects remain elusive. In the present study, we hypothesized that GLP-1R activation modulates dopaminetransporter (DAT) and thus dopamine (DA) homeostasis in striatum. This was evaluated in three different experiments: two preclinical and one clinical.METHODS: Rat striatal DA uptake, DA clearance and DAT cell surface expression was assessed following GLP-1 (7-36)-amide exposure in vitro. DA uptake in mice was assesed ex vivo following systemic treatment with the GLP-1R agonist exenatide. In addition, DA uptake was measured in GLP-1R knockout mice and compared with DA-uptake in wild type mice. In healthy humans, changes in DAT availability was assessed during infusion of exenatide measured by single-photon emission computed tomography imaging.RESULTS: In rats, GLP-1 (7-36)-amide increased DA uptake, DA clearance and DAT cell surface expression in striatum. In mice, exenatide did not change striatal DA uptake. In GLP-1R knockout mice, DA uptake was similar to what was measured in wildtype mice. In humans, systemic infusion of exenatide did not result in acute changes in striatal DAT availability.CONCLUSIONS: The GLP-1R agonist-induced modulation of striatal DAT activity in vitro in rats could not be replicated ex vivo in mice and in vivo in humans. Therefore, the underlying mechanisms of action for the GLP-1R agonists-induced efficacy in varios addiction-like behavioural models still remain.",
keywords = "Addiction, Dopamine transporter, Dopamine uptake, Glucagon-like peptide-1, Striatum",
author = "Jensen, {Mathias E} and Aurelio Galli and Morgane Thomsen and Jensen, {Kathrine L} and Thomsen, {Gerda K} and Klausen, {Mette K} and Tina Vilsb{\o}ll and Christensen, {Mikkel B} and Holst, {Jens J} and Anthony Owens and Sabrina Robertson and Lynette Daws and Daniele Zanella and Ulrik Gether and Knudsen, {Gitte M} and Anders Fink-Jensen",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
month = sep,
day = "1",
doi = "10.1016/j.neuint.2020.104772",
language = "English",
volume = "138",
pages = "104772",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Ltd",
}
RIS
TY - JOUR
T1 - Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent
AU - Jensen, Mathias E
AU - Galli, Aurelio
AU - Thomsen, Morgane
AU - Jensen, Kathrine L
AU - Thomsen, Gerda K
AU - Klausen, Mette K
AU - Vilsbøll, Tina
AU - Christensen, Mikkel B
AU - Holst, Jens J
AU - Owens, Anthony
AU - Robertson, Sabrina
AU - Daws, Lynette
AU - Zanella, Daniele
AU - Gether, Ulrik
AU - Knudsen, Gitte M
AU - Fink-Jensen, Anders
N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - INTRODUCTION: A solid body of preclinical evidence shows that glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the effects of substance use disorder related behaviors. The mechanisms underlying these effects remain elusive. In the present study, we hypothesized that GLP-1R activation modulates dopaminetransporter (DAT) and thus dopamine (DA) homeostasis in striatum. This was evaluated in three different experiments: two preclinical and one clinical.METHODS: Rat striatal DA uptake, DA clearance and DAT cell surface expression was assessed following GLP-1 (7-36)-amide exposure in vitro. DA uptake in mice was assesed ex vivo following systemic treatment with the GLP-1R agonist exenatide. In addition, DA uptake was measured in GLP-1R knockout mice and compared with DA-uptake in wild type mice. In healthy humans, changes in DAT availability was assessed during infusion of exenatide measured by single-photon emission computed tomography imaging.RESULTS: In rats, GLP-1 (7-36)-amide increased DA uptake, DA clearance and DAT cell surface expression in striatum. In mice, exenatide did not change striatal DA uptake. In GLP-1R knockout mice, DA uptake was similar to what was measured in wildtype mice. In humans, systemic infusion of exenatide did not result in acute changes in striatal DAT availability.CONCLUSIONS: The GLP-1R agonist-induced modulation of striatal DAT activity in vitro in rats could not be replicated ex vivo in mice and in vivo in humans. Therefore, the underlying mechanisms of action for the GLP-1R agonists-induced efficacy in varios addiction-like behavioural models still remain.
AB - INTRODUCTION: A solid body of preclinical evidence shows that glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the effects of substance use disorder related behaviors. The mechanisms underlying these effects remain elusive. In the present study, we hypothesized that GLP-1R activation modulates dopaminetransporter (DAT) and thus dopamine (DA) homeostasis in striatum. This was evaluated in three different experiments: two preclinical and one clinical.METHODS: Rat striatal DA uptake, DA clearance and DAT cell surface expression was assessed following GLP-1 (7-36)-amide exposure in vitro. DA uptake in mice was assesed ex vivo following systemic treatment with the GLP-1R agonist exenatide. In addition, DA uptake was measured in GLP-1R knockout mice and compared with DA-uptake in wild type mice. In healthy humans, changes in DAT availability was assessed during infusion of exenatide measured by single-photon emission computed tomography imaging.RESULTS: In rats, GLP-1 (7-36)-amide increased DA uptake, DA clearance and DAT cell surface expression in striatum. In mice, exenatide did not change striatal DA uptake. In GLP-1R knockout mice, DA uptake was similar to what was measured in wildtype mice. In humans, systemic infusion of exenatide did not result in acute changes in striatal DAT availability.CONCLUSIONS: The GLP-1R agonist-induced modulation of striatal DAT activity in vitro in rats could not be replicated ex vivo in mice and in vivo in humans. Therefore, the underlying mechanisms of action for the GLP-1R agonists-induced efficacy in varios addiction-like behavioural models still remain.
KW - Addiction
KW - Dopamine transporter
KW - Dopamine uptake
KW - Glucagon-like peptide-1
KW - Striatum
UR - http://www.scopus.com/inward/record.url?scp=85086715729&partnerID=8YFLogxK
U2 - 10.1016/j.neuint.2020.104772
DO - 10.1016/j.neuint.2020.104772
M3 - Journal article
C2 - 32464226
VL - 138
SP - 104772
JO - Neurochemistry International
JF - Neurochemistry International
SN - 0197-0186
M1 - 104772
ER -